Fluoguide reported Q1 results and provided an update on its clinical programme that will see head and neck cancer increasingly prioritised over lung cancer in the development timeline. We expect positive readouts from several major trials over the remainder of 2023 that investors should keep a close eye on, as they are major de-risking events in our view.

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.